Cannae Holdings Valuation
Is CQ2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CQ2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CQ2's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CQ2's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CQ2?
Key metric: As CQ2 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CQ2's PS Ratio? | |
|---|---|
| PS Ratio | 2.9x |
| Sales | US$461.90m |
| Market Cap | US$1.36b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.3x |
| Enterprise Value/EBITDA | -12.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CQ2's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.2x | ||
CHG CHAPTERS Group | 6.2x | 20.2% | €538.0m |
PZS Scherzer | 9.8x | 10.0% | €65.3m |
HYQ Hypoport | 3.1x | 11.5% | €1.3b |
PBB Deutsche Pfandbriefbank | 1.9x | 12.0% | €679.1m |
CQ2 Cannae Holdings | 2.9x | 1.9% | €1.4b |
Price-To-Sales vs Peers: CQ2 is good value based on its Price-To-Sales Ratio (2.9x) compared to the peer average (5.2x).
Price to Sales Ratio vs Industry
How does CQ2's PS Ratio compare vs other companies in the DE Diversified Financial Industry?
Price-To-Sales vs Industry: CQ2 is expensive based on its Price-To-Sales Ratio (2.9x) compared to the European Diversified Financial industry average (2x).
Price to Sales Ratio vs Fair Ratio
What is CQ2's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.9x |
| Fair PS Ratio | 1.5x |
Price-To-Sales vs Fair Ratio: CQ2 is expensive based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €20.40 | €26.52 +30.0% | 5.1% | €28.41 | €25.57 | n/a | 3 |
| Nov ’25 | €18.10 | €24.70 +36.5% | 3.0% | €25.62 | €23.79 | n/a | 3 |
| Oct ’25 | €16.90 | €24.70 +46.2% | 3.0% | €25.62 | €23.79 | n/a | 3 |
| Sep ’25 | €17.80 | €24.70 +38.8% | 3.0% | €25.62 | €23.79 | n/a | 3 |
| Aug ’25 | €18.40 | €26.61 +44.6% | 5.9% | €28.77 | €25.06 | n/a | 3 |
| Jul ’25 | €16.60 | €26.61 +60.3% | 5.9% | €28.77 | €25.06 | n/a | 3 |
| Jun ’25 | €16.70 | €26.61 +59.3% | 5.9% | €28.77 | €25.06 | n/a | 3 |
| May ’25 | €18.50 | €26.71 +44.4% | 5.6% | €28.55 | €24.87 | n/a | 3 |
| Apr ’25 | €20.40 | €25.70 +26.0% | 7.7% | €28.45 | €23.86 | n/a | 3 |
| Mar ’25 | €20.00 | €25.20 +26.0% | 9.6% | €28.58 | €23.05 | n/a | 3 |
| Feb ’25 | €18.60 | €25.21 +35.6% | 8.0% | €28.01 | €23.35 | n/a | 3 |
| Jan ’25 | €17.80 | €25.21 +41.6% | 8.0% | €28.01 | €23.35 | n/a | 3 |
| Dec ’24 | €16.30 | €25.21 +54.7% | 8.0% | €28.01 | €23.35 | n/a | 3 |
| Nov ’24 | €15.50 | €30.84 +99.0% | 12.3% | €33.99 | €25.49 | €18.10 | 3 |
| Oct ’24 | €18.10 | €30.55 +68.8% | 10.8% | €33.33 | €25.92 | €16.90 | 3 |
| Sep ’24 | €17.90 | €30.55 +70.7% | 10.8% | €33.33 | €25.92 | €17.80 | 3 |
| Aug ’24 | €18.30 | €31.06 +69.7% | 13.4% | €35.63 | €25.58 | €18.40 | 3 |
| Jul ’24 | €18.30 | €31.06 +69.7% | 13.4% | €35.63 | €25.58 | €16.60 | 3 |
| Jun ’24 | €18.10 | €31.57 +74.4% | 13.4% | €36.21 | €26.00 | €16.70 | 3 |
| May ’24 | €16.30 | €33.77 +107.2% | 10.1% | €37.42 | €29.21 | €18.50 | 3 |
| Apr ’24 | €17.60 | €35.70 +102.9% | 7.6% | €38.86 | €32.23 | €20.40 | 3 |
| Mar ’24 | €20.80 | €35.70 +71.7% | 7.6% | €38.86 | €32.23 | €20.00 | 3 |
| Feb ’24 | €22.20 | €33.84 +52.4% | 11.2% | €38.76 | €29.53 | €18.60 | 3 |
| Jan ’24 | €19.00 | €35.97 +89.3% | 11.2% | €41.21 | €31.40 | €17.80 | 3 |
| Dec ’23 | €22.20 | €35.97 +62.0% | 11.2% | €41.21 | €31.40 | €16.30 | 3 |
| Nov ’23 | €23.40 | €35.49 +51.7% | 11.4% | €39.54 | €31.43 | €15.50 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Yeahka
HK$4.2b
An investment holding company, provides payment and business services to merchants and consumers in the People’s Republic of China.
4YE
HK$1.18
7D
-5.6%
1Y
-25.8%
ORIX
JP¥3.8t
Provides diversified financial services in Japan, the United States, Asia, Europe, Australasia, and the Middle East.
OIX
JP¥20.60
7D
2.0%
1Y
24.1%
Mutares SE KGaA
€494.3m
A private equity firm specializing in investments in secondary direct, special situations, bridge financing, recapitalization, distressed/vulture, management succession, reorganization, carve-outs, turnarounds, spin-offs and re-funding.
MUX
€22.40
7D
0%
1Y
-29.6%